FRAXA Research Foundation is proud to make a grant of $90,000 over 2014-2015 to Margaret King, PhD. The goal of this project is to identify new approaches to clinical trial design for Fragile X pharmaceuticals.
Read moreFinucane, Brenda
Brenda Finucane, MS, is a genetic counselor at Geisinger Health System. She is particularly interested in syndromes such as Fragile X, Smith-Magenis, and 15q duplications.